Peptides studied across the HPG axis and CNS sexual-response pathways.
This area covers peptides acting on the central and endocrine control of sexual and reproductive function. Two pathways dominate the literature: central melanocortin signaling, studied for sexual-response disorders, and kisspeptin signaling, the upstream regulator of the hypothalamic–pituitary–gonadal (HPG) axis.
Endpoints range from hypoactive sexual desire disorder (HSDD) and CNS-mediated arousal to reproductive-endocrine applications such as hypothalamic amenorrhea and the study of puberty. Because these peptides act centrally and on hormone cascades, dose timing and feedback regulation are key research variables.
Two dominate the literature: central melanocortin signaling, studied for sexual-response disorders, and kisspeptin signaling, the upstream regulator of the HPG axis.
Research contexts include hypoactive sexual desire disorder (HSDD), CNS-mediated arousal, hypothalamic amenorrhea, and the study of puberty.
Because these peptides act centrally and on hormone cascades, timing and feedback regulation strongly influence the response observed in studies.
How to weigh this evidence
Preclinical, observational, and randomized findings carry very different weight. The evidence hierarchy shows how to rank what you read before drawing conclusions.
Put the science to work — interactive utilities that run right here.
Ask in plain language — citation-backed answers from PubMed, PubChem & trials.
Build a peptide residue by residue with live chemistry, challenges & XP.
Sequence properties — pI, ε280, net charge & synthesis-difficulty flags.
Paste a certificate of analysis; grade its transparency and spot red flags.
Dose, dilution and syringe-unit math for reconstituting a vial.
Search PubChem for structures, molecular formulae and weights.
Which peptides are best studied for sexual & reproductive health, how they compare, and what the clinical evidence shows — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.